Novavax Inc (NVAX) stock
NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.96−0.10 (-1.24%)
Close on Nov 17, 2026Market cap $1.31BP/E –Yield –
Novavax pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Novavax's pe ratio was 3.1× on Apr 30, 2026.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Apr 30, 2026 | 3.1× | −0.7 |
| 2025 | Dec 31, 2025 | 3.8× | – |
See a number that looks wrong?